Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3855937 | 0.90 | CYP4F2 (0.52) | PARP1CYP4F2CYP4A11LOXL2MEP1B | |
| SCHEMBL12808726 | 0.85 | FOLH1 (0.56) | CYP4F2CYP4A11RAB9ASMN1; SMN2 | |
| SCHEMBL15019978 | 0.83 | CYP4F2 (0.73) | PARP1CYP4F2CYP4A11LOXL2KDM4E | |
| SCHEMBL2824632 | 0.83 | PARP1 (0.56) | PARP1CYP4F2CYP4A11LOXL2MEP1B | |
| SCHEMBL7771633 | 0.81 | PARP1 (0.53) | PARP1CYP4F2CYP4A11LOXL2MEP1B | |
| SCHEMBL31487553 | 0.81 | PARP1 (0.53) | PARP1CYP4F2CYP4A11LOXL2MEP1B | |
| SCHEMBL4165717 | 0.80 | CHEK1 (0.50) | PARP1LOXL2MEP1BF10KDM4E | |
| SCHEMBL10144991 | 0.80 | CYP4F2 (0.69) | CYP4F2CYP4A11LOXL2MEP1BNPC1 | |
| Hydrochloric Acid SCHEMBL27543812 | 0.79 | PARP1 (0.52) | PARP1CYP4F2CYP4A11LOXL2MEP1B | |
| SCHEMBL8342426 | 0.79 | TAAR1 (0.55) | PARP1LOXL2MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544808-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | claimed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| US-7253283-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | claimed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | claimed |
| US-6995181-B2 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB CO. (US) | 2006-02-07 | — | — | US | claimed |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | VACCARO WAYNE (US) | 2005-08-04 | — | — | US | claimed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | claimed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| US-7544808-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | VACCARO WAYNE (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270453-A1 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | PARP1 1547/4885CYP4F2 1337/4885CYP4A11 111/4885 |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKBIA, NFKB1 | PARP1 1547/4885CYP4F2 1337/4885CYP4A11 111/4885 |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, NR3C2, MC2R | PARP1 3430/4885CYP4F2 689/4885CYP4A11 234/4885 |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, MC2R, NR3C2 | PARP1 4705/4885CYP4F2 474/4885CYP4A11 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.